Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Factors Associated with Gastric and Duodenal Neuroendocrine Tumor Development

  • Kwangwoo Nam (Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine) ;
  • Su Youn Nam (Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University)
  • Received : 2024.02.26
  • Accepted : 2024.03.23
  • Published : 2024.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence and prevalence of upper gastrointestinal neuroendocrine tumors (NETs), including gastric NETs (GNETs) and duodenal NETs (DNETs), have been gradually increasing. These trends may be associated with the increased use of health checkups, which includes upper endoscopy, in conjunction with better disease recognition. However, the clinical factors associated with GNETs and DNETs remain unknown; previous studies revealed discrepancies. Recently, metabolic disorders have been indicated as potential factors that are associated with GNETs and DNETs. This review summarizes the results of previous studies and briefly introduces the results of a recent Korean multicenter study on the factors associated with GNETs and DNETs.

Keywords

Acknowledgement

This study was supported by the Korean Society of Gastrointestinal Cancer Research (2021). The funding source did not play any role in the planning or implementation of this study, interpreting the results, or writing the manuscript. The views and opinions expressed are those of the authors and do not necessarily reflect those of the supporting institutions.

References

  1. Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin 2018;68:471-487. https://doi.org/10.3322/caac.21493
  2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335-1342. https://doi.org/10.1001/jamaoncol.2017.0589
  3. Ahmed M. Gastrointestinal neuroendocrine tumors in 2020. World J Gastrointest Oncol 2020;12:791-807. https://doi.org/10.4251/wjgo.v12.i8.791
  4. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072. https://doi.org/10.1200/JCO.2007.15.4377
  5. Rossi RE, Massironi S. The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues. J Clin Med 2022;11:3794. https://doi.org/10.3390/jcm11133794
  6. Park MI. Endoscopic treatment for early foregut neuroendocrine tumors. Clin Endosc 2013;46:450-455. https://doi.org/10.5946/ce.2013.46.5.450
  7. Kwon YH, Jeon SW, Kim GH, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol 2013;19:8703-8708. https://doi.org/10.3748/wjg.v19.i46.8703
  8. Kim GH, Kim JI, Jeon SW, et al. Endoscopic resection for duodenal carcinoid tumors: a multicenter, retrospective study. J Gastroenterol Hepatol 2014;29:318-324. https://doi.org/10.1111/jgh.12390
  9. Rossi RE, Rausa E, Cavalcoli F, Conte D, Massironi S. Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. Scand J Gastroenterol 2018;53:835-842. https://doi.org/10.1080/00365521.2018.1468479
  10. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer 2008;123:867-873. https://doi.org/10.1002/ijc.23529
  11. Santos AP, Santos AC, Castro C, et al. Visceral obesity and metabolic syndrome are associated with well-differentiated gastroenteropancreatic neuroendocrine tumors. Cancers (Basel) 2018;10:293. https://doi.org/10.3390/cancers10090293
  12. Katz LH, Levi Z, Twig G, et al. Risk factors associated with gastroenteropancreatic neuroendocrine tumors in a cohort of 2.3 million Israeli adolescents. Int J Cancer 2018;143:1876-1883. https://doi.org/10.1002/ijc.31589
  13. Soto-Solis R, Romano-Munive AF, Santana de Anda K, Barreto-Zuniga R. Factors related to gastric neuroendocrine tumors. Rev Gastroenterol Mex (Engl Ed) 2019;84:52-56. https://doi.org/10.1016/j.rgmxen.2018.06.007
  14. Campana D, Ravizza D, Ferolla P, et al. Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study. Endocrine 2017;56:633-638. https://doi.org/10.1007/s12020-016-1099-y
  15. Massironi S, Campana D, Partelli S, et al. Heterogeneity of duodenal neuroendocrine tumors: an Italian multicenter experience. Ann Surg Oncol 2018;25:3200-3206. https://doi.org/10.1245/s10434-018-6673-5
  16. Rossi RE, Milanetto AC, Andreasi V, et al. Risk of preoperative understaging of duodenal neuroendocrine neoplasms: a plea for caution in the treatment strategy. J Endocrinol Invest 2021;44:2227-2234. https://doi.org/10.1007/s40618-021-01528-1
  17. Giannetta E, Guarnotta V, Rota F, et al. A rare rarity: neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol 2019;137:92-107. https://doi.org/10.1016/j.critrevonc.2019.02.012
  18. Wu IC, Chu YY, Wang YK, et al. Clinicopathological features and outcome of esophageal neuroendocrine tumor: a retrospective multicenter survey by the digestive endoscopy society of Taiwan. J Formos Med Assoc 2021;120:508-514. https://doi.org/10.1016/j.jfma.2020.06.024
  19. Chun HJ, Park SJ, Lim YJ, Song SY. Gastrointestinal cancer: a comprehensive guide to diagnosis and management. Singapore: Springer, 2023. p.437-446.
  20. Feola T, Puliani G, Sesti F, et al. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study. J Endocrinol Invest 2022;45:849-857. https://doi.org/10.1007/s40618-021-01715-0
  21. Barrea L, Muscogiuri G, Modica R, et al. Cardio-metabolic indices and metabolic syndrome as predictors of clinical severity of gastroenteropancreatic neuroendocrine tumors. Front Endocrinol (Lausanne) 2021;12:649496. https://doi.org/10.3389/fendo.2021.649496
  22. Scherubl H, Jensen RT, Cadiot G, Stolzel U, Kloppel G. Management of early gastrointestinal neuroendocrine neoplasms. World J Gastrointest Endosc 2011;3:133-139. https://doi.org/10.4253/wjge.v3.i7.133
  23. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182-188. https://doi.org/10.1111/his.13975
  24. Nam K, Nam SY, Park JC, et al. Factors associated with gastric and duodenal neuroendocrine tumors: a multicenter case-control study. Dig Liver Dis 2024. https://doi.org/10.1016/j.dld.2024.01.210